How LightWay works
Every case starts the same way: the record, and the tumor's own sequencing. Where the patient is right now decides which of two ways we help. This page goes deeper on reaching a treatment: what the analysis looks at, how the options are graded, and how access is opened. The personalized vaccine is worked out with each patient in conversation.
One record, one sequencing run, one question.
Is there measurable disease right now? The answer opens one way or the other, and sometimes both.
Patient record opened
Clinical history, imaging, labs
Tumor sequencing
DNA, RNA, and a matched normal sample
Where is the patient now?
No measurable disease and time to prepare, or active disease that needs options now
Personalized vaccine
No evidence of disease after standard of care, tumor tissue available.A vaccine designed from the tumor's own mutations
Made for one patient, given by a physician
Reaching a treatment
Active or recurrent disease, options needed now.Tumor analysis
DNA, RNA, and expression: every vulnerability mapped
Grade by evidence
Every option the biology supports, with its evidence trail attached
Open the access path
For each option: how you actually get it
R1On-labelR2Off-labelR3Clinical trialsR4Expanded accesspreparedA report tells you what your tumor has. This tells you what that opens.
How strong the evidence is for each option, and how you get to it.
The whole tumor, not a panel
Whole-exome DNA, RNA, and a matched normal sample from the patient, so the analysis can tell a tumor's mutations from the patient's own, and see what the tumor is actually expressing, not only what it carries.
Every vulnerability the biology shows
Mutations, fusions, expression levels, and immune signals are read together. The output is a set of candidate targets and the therapies that act on them, each grounded in the patient's own DNA and RNA evidence.
Ranked by evidence, and by how much it could matter
Every option is graded on the strength of the evidence behind it and the size of the effect it could have for this tumor. Approved uses, off-label uses, trials, and expanded access all sit on the same scale, so they can be compared honestly.
Each option comes with its way in
For an approved or off-label drug, what the prescribing physician needs. For a trial, the eligibility questions and the outreach. For expanded access, the evidence package a physician needs to request it, prepared before it is needed.
A case is not a report that gets written once.
Three things stay true for as long as we are on it.
New trials and new evidence, daily and weekly
The case is re-run against what has changed: trials that opened or closed, and research that bears on this tumor.
Every recommendation points to its source
Nothing rests on "trust us." Each option links to the evidence and the finding in the record that support it.
The ranking is a judgment, made by experts
The software finds and grades the options. Which ones actually fit this patient, and in what order, is decided by experts who have read the whole record.
If this is the situation you are in, tell us about the case.
A few lines is enough to start.